Retigabine is used as an anticonvulsant medication, primarily in the treatment of partial-onset seizures in patients with epilepsy. It works by enhancing the activity of potassium channels in the brain, specifically the KCNQ (Kv7) channels, which helps stabilize neuronal membranes and reduce excessive electrical activity that can lead to seizures. Retigabine is typically prescribed as an adjunctive therapy when other anti-epileptic drugs are not fully effective. Its use has been limited in some regions due to potential side effects, including urinary retention, cognitive disturbances, and retinal discoloration, leading to careful patient monitoring during treatment.